

Report to:	NHS Hull CCG Board.
Date of Meeting:	26 March 2021
Title of Report:	Hull CCG Research & Development 6 monthly Status Report (April 2020-Oct 2020)
Presented by:	Deborah Lowe, Deputy Director of Quality, Clinical Governance/Lead Nurse
Author:	Dr Marie Girdham R & D Lead Nurse Manager

STATUS OF THE REPORT:

To approve	<input type="checkbox"/>	To endorse	<input type="checkbox"/>
To ratify	<input type="checkbox"/>	To discuss	<input checked="" type="checkbox"/>
To consider	<input checked="" type="checkbox"/>	For information	<input type="checkbox"/>
To note	<input type="checkbox"/>		

PURPOSE OF REPORT:

The purpose of the report is to provide the Board with the Research and Development (R&D) update for the 6 monthly period of 1st April 2020 to 1st October 2020.

The update report focuses on the R & D response to the COVID 19 situation and the proposed RESTART framework for non COVID studies and the assurances that are in place to potentially restart the Non-COVID R & D work.

The report recognises the role of R & D in the pandemic and provides the evidence that NHS Hull Clinical Commissioning Group (ERY CCG) still continues to maintain and develop its statutory duty to 'promote research, innovation and the use of research evidence' (Health and Social Care Act, 2012).

The report presents an update on the following:

- R & D response to COVID 19 and the Urgent Public Health(UPH) NIHR portfolio Study Activity
- Status update(s) on CCG small grants funded projects
- Status update on NHS Hull open Excess treatment costs
- Update(s) on R&D strategic work into 2020/21

RECOMMENDATIONS:

- It is recommended that the NHS Hull CCG Board note the contents of Research and Development 6 monthly Status report- April 2020- October 2020

REPORT EXEMPT FROM PUBLIC DISCLOSURENo Yes

If yes, detail grounds for exemption

CCG STRATEGIC OBJECTIVE *(See guidance notes on page 4)*

The following report aligns with strategic objectives 1, 5, 8 and 9

Short summary as to how the report links to the CCG's strategic objectives

The Research and Development report - April 2020 to October 2020 focuses on the R & D response to the COVID 19 situation and the proposed RESTART framework for non COVID studies.

The report also highlights what locally grown 'green shoot' work is still being progressed and demonstrates what assurances are in place and what adjustments have been needed to the study design or methodology in response to the pandemic.

IMPLICATIONS: *(summary of key implications, including risks, associated with the paper),*

Finance	No impact identified financially for Hull CCG
HR	No risks identified
Quality	Support for involving the patients in research studies is one of the indicators for quality health care and a mandatory part of the quality reports accounts.
Safety	The legislative frameworks that support R & D link into the Health Research authority (HRA) and set out the safety requirements and assurances needed to minimise any risk to patient safety. The HRA have put additional measures in place to essentially review Urgent Public Health COVID 19 studies, the information has been updated on the HRA web site.

ENGAGEMENT: *(Explain what engagement has taken place e.g. Partners, patients and the public prior to presenting the paper and the outcome of this)*

All National Institute of Health Research (NIHR) portfolio-adopted research studies that include excess treatment costs require to be compliant with DOH and National Health Service (NHS) policies on having patient input provided in relation to the design and rationale for research studies, including an opportunity to be fully informed about the study procedures.

All research projects supported by NHS Hull CCG require demonstrating patient involvement in the project design, rationale and /or participation including provision of full information and formal

consent procedures consistent with the UK Policy framework for Health and Social Care Research (2017).

LEGAL ISSUES: (*Summarise key legal issues / legislation relevant to the report*)

As recognised in the Health and Social Care Act (2012) the CCG is mandated to promote research and the use of research evidence

EQUALITY AND DIVERSITY ISSUES: (*summary of impact, if any, of CCG's duty to promote equality and diversity based on Equality Impact Analysis (EIA). All reports relating to new services, changes to existing services or CCG strategies / policies must have a valid EIA and will not be received by the Committee if this is not appended to the report*)

	Tick relevant box
An Equality Impact Analysis/Assessment is not required for this report.	√
An Equality Impact Analysis/Assessment has been completed and approved by the lead Director for Equality and Diversity. As a result of performing the analysis/assessment there are no actions arising from the analysis/assessment.	
An Equality Impact Analysis/Assessment has been completed and there are actions arising from the analysis/assessment and these are included in section xx in the enclosed report.	

THE NHS CONSTITUTION: (*How the report supports the NHS Constitution*)

The NHS Constitution confirms the commitment of the NHS 'to the promotion and conduct of research.' NHS Hull CCG is fully compliant with this provision of the NHS Constitution.